<DOC>
	<DOCNO>NCT00613106</DOCNO>
	<brief_summary>The purpose study evaluate safety long-term treatment HZT-501 .</brief_summary>
	<brief_title>Double-Blind Follow-on Safety Study HZT-501 ( Ibuprofen 800 mg/Famotidine 26.6 mg ) Subjects Who Have Completed Participation HZ-CA-301 ( NCT00450658 ) HZ-CA-303 ( NCT00450216 )</brief_title>
	<detailed_description>Subject complete 24-week Treatment Period Horizon Protocol HZ-CA-301 HZ-CA-303 without develop upper gastrointestinal ulcer expect continue require daily administration NSAID next 6 month receive treatment study medication receive participate HZ-CA-301 HZ-CA-303 .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Nociceptive Pain</mesh_term>
	<mesh_term>Famotidine</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Expected continue require daily administration NSAID least come 6 month . Subject complete 24week Treatment period either Horizon Protocol HZCA301 HZCA303 Subject n't meet Inclusion Exclusion Criteria Horizon Protocol HZCA301 HZCA303 Subject develop experience follow either HZCA301 HZCA303 Malignant Disease gastrointestinal tract Erosive esophagitis Clinically significant cardiac , renal hepatic disease Uncontrolled diabetes Positive pregnancy test Study Day 0 Please note additional criterion . The study center determine meet criterion .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>81 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>